EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Progression in Myeloid Neoplasms: Beyond the Myeloblast

Carlos Faria, Alexandar Tzankov

Pathobiology · 2024

DOI: 10.1159/000530940 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathobiology, 2024. Verfasst von Carlos Faria und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomical Pathology, Coimbra University Hospital, Coimbra, Portugal. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disease progression in myelodysplastic syndromes (MDS), myelodysplastic-myeloproliferative neoplasms (MDS/MPN), and myeloproliferative neoplasms (MPN), altogether referred to as myeloid neoplasms (MN), is a major source of mortality. Apart from transformation to acute myeloid leukemia, the clinical progression of MN is mostly due to the overgrowth of pre-existing hematopoiesis by the MN without an additional transforming event. Still, MN may evolve along other recurrent yet less well-known scenarios: (1) acquisition of MPN features in MDS or (2) MDS features in MPN, (3) progressive myelofibrosis (MF), (4) acquisition of chronic myelomonocytic leukemia (CMML)-like characteristics in MPN or MDS, (5) development of myeloid sarcoma (MS), (6) lymphoblastic (LB) transformation, (7) histiocytic/dendritic outgrowths. These MN-transformation types exhibit a propensity for extramedullary sites (e.g., skin, lymph nodes, liver), highlighting the importance of lesional biopsies in diagnosis. Gain of distinct mutations/mutational patterns seems to be causative or at least accompanying several of the above-mentioned scenarios. MDS developing MPN features often acquire MPN driver mutations (usually JAK2), and MF. Conversely, MPN gaining MDS features develop, e.g., ASXL1, IDH1/2, SF3B1, and/or SRSF2 mutations. Mutations of RAS-genes are often detected in CMML-like MPN progression. MS ex MN is characterized by complex karyotypes, FLT3 and/or NPM1 mutations, and often monoblastic phenotype. MN with LB transformation is associated with secondary genetic events linked to lineage reprogramming leading to the deregulation of ETV6, IKZF1, PAX5, PU.1, and RUNX1. Finally, the acquisition of MAPK-pathway gene mutations may shape MN toward histiocytic differentiation. Awareness of all these less well-known MN-progression types is important to guide optimal individual patient management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloproliferative DisordersMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative DiseasesLeukemia, Myeloid, AcuteHumansGranulocyte Precursor CellsMutation

Stichwörter der Autor:innen

MutationsMyelofibrosisMyeloid neoplasmProgressionTransformation

Autor:innen und Institutionen

  • Department of Anatomical Pathology, Coimbra University Hospital, Coimbra, Portugal.
  • Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.

Zitieren

APA

Faria, C., & Tzankov, A. (2024). Progression in Myeloid Neoplasms: Beyond the Myeloblast. Pathobiology. https://doi.org/10.1159/000530940

Vancouver

Faria C, Tzankov A. Progression in Myeloid Neoplasms: Beyond the Myeloblast. Pathobiology. 2024. doi:10.1159/000530940

BibTeX
@article{Faria2024,
  author = {Faria, Carlos and Tzankov, Alexandar},
  title = {Progression in Myeloid Neoplasms: Beyond the Myeloblast},
  journal = {Pathobiology},
  year = {2024},
  doi = {10.1159/000530940}
}
Kostenlos starten →